Want to see DYN full AI Analyst Report?
Top Page
Dyne Therapeutics
(NASDAQ:DYN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$20.00
▼(-24.07% Downside)
Action:Reiterated
Date:09/09/26
Overall score is held down primarily by weak financial performance (no revenue, large and worsening losses, and substantial cash burn) and bearish technical trend/momentum (trading below major moving averages with negative MACD). Offsetting support comes from corporate events that strengthen funding runway and advance a key regulatory milestone (DYNE-251 Priority Review), but valuation is still constrained by ongoing losses and no dividend support.
Positive Factors
FORCE platform and pipeline
Dyne’s FORCE platform targets delivery to muscle and other relevant tissues, supporting a differentiated approach to genetically driven neuromuscular diseases. Its pipeline across myotonic dystrophy and Duchenne muscular dystrophy provides multiple development paths that could support durable strategic value if clinical progress continues.
Negative Factors
No commercial revenue
Dyne has not yet demonstrated product revenue or commercial economics, leaving its business model dependent on future clinical and regulatory success. Until a therapy is approved and launched, the company cannot rely on recurring sales to fund operations or validate the long-term profitability of its platform.
Read all positive and negative factors
Positive Factors
Negative Factors
FORCE platform and pipeline
Dyne’s FORCE platform targets delivery to muscle and other relevant tissues, supporting a differentiated approach to genetically driven neuromuscular diseases. Its pipeline across myotonic dystrophy and Duchenne muscular dystrophy provides multiple development paths that could support durable strategic value if clinical progress continues.
Read all positive factors
Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.58B
Dividend YieldN/A
Average Volume (3M)2.24M
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue GrowthN/A
EPS Growth13.71%
CountryUS
Employees289
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.33
Shares Outstanding186,746,430
10 Day Avg. Volume3,052,793
30 Day Avg. Volume2,240,611
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.46Price Target Upside42.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.61
Revenue Forecast (FY)N/A
Dyne Therapeutics Business Overview & Revenue Model
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, ...
How the Company Makes Money
Dyne Therapeutics primarily makes money through a mix of (1) collaboration/partnering revenue and (2) financing, because it is a clinical-stage company without broadly marketed commercial products.
1) Collaboration and partnership revenue: When D...
Dyne Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.07M | -2.05M | -2.24M | -2.46M | 0.00 | 0.00 |
| EBITDA | -495.35M | -437.97M | -315.18M | -233.48M | -163.50M | -148.20M |
| Net Income | -519.41M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
Balance Sheet | ||||||
| Total Assets | 994.01M | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Cash, Cash Equivalents and Short-Term Investments | 898.48M | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Total Debt | 19.87M | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M |
| Total Liabilities | 291.86M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Stockholders Equity | 702.15M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
Cash Flow | ||||||
| Free Cash Flow | -499.22M | -405.13M | -294.75M | -188.89M | -156.71M | -123.18M |
| Operating Cash Flow | -477.82M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Investing Cash Flow | -44.17M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Financing Cash Flow | 713.47M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
Dyne Therapeutics Technical Analysis
Negative
26.34
Price Trends
24.63
Negative
21.55
Negative
19.90
Negative
Market Momentum
-1.14
Positive
18.52
Positive
24.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 26.34 is above the 20-day moving average (MA) of 24.77, above the 50-day MA of 24.63, and above the 200-day MA of 19.90, indicating a bearish trend. The MACD of -1.14 indicates Positive momentum. The RSI at 18.52 is Positive, neither overbought nor oversold. The STOCH value of 24.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.
Dyne Therapeutics Risk Analysis
Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dyne Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $3.00B | 105.89 | 15.05% | ― | 76.11% | ― | |
54 Neutral | $2.33B | -14.25 | -9.96% | ― | -20.44% | -349.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.78B | -186.25 | -2.35% | ― | 20.19% | ― | |
45 Neutral | $3.58B | -5.53 | -64.30% | ― | ― | 13.71% | |
45 Neutral | $2.60B | -29.72 | -7.70% | 4.80% | 158.88% | 81.95% | |
43 Neutral | $5.93B | -14.75 | -72.57% | ― | ― | 4.92% |
* Healthcare Sector Average
DYN
Dyne Therapeutics
18.42
5.24
39.76%
SRPT
Sarepta Therapeutics
20.52
2.61
14.57%
COGT
Cogent Biosciences
34.08
21.27
166.04%
ARQT
Arcutis Biotherapeutics
23.38
5.69
32.17%
BEAM
Beam Therapeutics
24.37
2.82
13.09%
IMCR
Immunocore Holdings
33.58
-2.99
-8.18%
Dyne Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
Positive
Jul 22, 2026
On July 21, 2026, Dyne Therapeutics priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, with gross proceeds expected to be about $375.2 million and net proceeds estimated at $352.1 million. The ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Dyne Therapeutics Advances DYNE-251 With FDA Priority Review
Positive
Jul 20, 2026
On July 20, 2026, Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (DYNE-251) to treat individuals with Duchenne muscular dystrophy am...
Executive/Board Changes
Dyne Therapeutics Names Barry Greene Independent Board Director
Positive
Jun 22, 2026
On June 22, 2026, Dyne Therapeutics, Inc. appointed Barry E. Greene as a Class I independent director to its board, with a term extending until the 2027 Annual Meeting of Stockholders and continuation subject to standard conditions such as death, ...
Business Operations and StrategyPrivate Placements and Financing
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
Positive
Jun 17, 2026
On June 16, 2026, Dyne Therapeutics entered into a second amendment to its loan and security agreement with Hercules Capital and other lenders, expanding its debt facility to up to $400 million and relaxing certain financial covenants. The amendme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.